1177.HK
EquitySINO BIOPHARM
Health Care · Biotechnology
$5.84
+5.84 (+0.00%)
Open
N/A
Day Range
$5.82 - $5.88
52W Range
$3.15 - $9.12
Volume
572K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Great Elm Capital: Q4 Earnings Snapshot
Q4 Earnings Highlights: Procter & Gamble (NYSE:PG) Vs The Rest Of The Household Products Stocks
Senseonics (SENS) Q4 2025 Earnings Call Transcript
Taiwan Showcases "Adventures Await" at the 2026 Vancouver Outdoor Adventure & Travel Show
Ecuador launches joint anti-drug operations with US
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | $22.81 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.26 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $234.26 | N/A | 2.84% | +0.00% |
| AGEN | Agenus Inc. | $3.34 | N/A | - | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.71 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $60.77 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| A | Agilent Technologies, Inc. | $118.17 | N/A | 0.85% | +0.00% |
About SINO BIOPHARM
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
www.sinobiopharm.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+50.0%
3Y CAGR
-3.5%
5Y CAGR
N/A
10Y CAGR
N/A
Loading financial data...
Revenue & Earnings
No financial statement data available for 1177.HK.